GU
GUTS.US Fractyl Health, Inc. Common Stock
- Market cap
- USD 12.0M
- P/E
- -
- P/B
- 5.06x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is GUTS.US undervalued?
Graham numberThe Graham number of Fractyl Health, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fractyl Health, Inc. Common Stock fundamental analysis
No fundamental analysis for Fractyl Health, Inc. Common Stock yet.
Fractyl Health, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is desi…
Full company profileFractyl Health, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fractyl Health, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 120K | 93.0K | 0.00 | 0.00 |
| Gross Profit | -893K | -770K | -676K | -452K | 43.0K | 43.0K | -1.13M | - |
| Operating Income | -29.9M | -29.0M | -36.9M | -49.4M | -50.8M | -93.5M | -96.8M | -84.3M |
| EBITDA | -29.0M | -28.2M | -36.6M | -46.0M | -50.6M | -68.0M | -140M | -78.9M |
| Net Income | -30.6M | -30.5M | -38.7M | -46.5M | -77.1M | -68.7M | -141M | -80.1M |
| EPS | -7.71 | -7.68 | -9.76 | -12 | -1.62 | -19 | -11 | -6.06 |
| Balance Sheet | ||||||||
| Total Assets | 8.93M | 34.8M | 103M | 61.0M | 76.2M | 108M | 121M | 82.0M |
| Total Liabilities | 153M | 19.8M | 312M | 313M | 401M | 79.7M | 112M | 83.6M |
| Shareholders' Equity | -144M | 15.0M | -209M | -252M | -325M | 28.4M | 9.46M | -1.67M |
| Cash & Short-term Investments | 5.79M | 29.1M | 95.5M | 49.3M | 33.2M | 67.5M | 81.5M | 47.1M |
| Total Debt | 14.9M | 15.3M | 304M | 307M | 86.4M | 62.5M | 61.6M | 60.7M |
| Cash Flow | ||||||||
| Operating Cash Flow | -27.7M | -31.1M | -33.5M | -46.2M | -42.8M | -65.5M | -90.3M | -79.6M |
| Capital Expenditure | 97.0K | 2.00K | 51.0K | 56.0K | 359K | 1.77M | 557K | 4.00K |
| Free Cash Flow | -27.8M | -31.1M | -33.5M | -46.3M | -43.2M | -67.3M | -90.9M | -79.6M |
| Ratios | ||||||||
| ROE | - | -203.9% | - | - | - | -241.7% | -1,490.3% | - |
| ROA | -342.4% | -87.7% | -37.8% | -76.2% | -101.2% | -63.6% | -116.1% | -97.7% |
| Net Profit Margin | - | - | - | - | -64,242.5% | -73,864.5% | - | - |
| Debt to Equity | - | 1.02x | - | - | - | 2.20x | 6.52x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fractyl Health, Inc. Common Stock dividends
Fractyl Health, Inc. Common Stock has not paid dividends in the last 7 fiscal years.
Last stock split: 1:12 on Oct 5, 2026.
Who owns Fractyl Health, Inc. Common Stock
- Insiders 1.45%
- Institutions 49.26%
- Public & others 49.29%
- Shares outstanding 13.3M
- Free float 12.1M
Top funds holding GUTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.62M | 2.90% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 752K | 0.47% | +26.76% | Sep 2026 |
| Abante Quant Value FI | 716K | 0.45% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 214K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 174K | 0.11% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 150K | 0.09% | +272.76% | Jun 2026 |
| Vanguard Balanced Index Inv | 71.6K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 67.8K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 41.3K | 0.03% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 28.3K | 0.02% | 0.00% | Aug 2026 |
| Victory Extended Market Index | 15.5K | 0.01% | +3.49% | Sep 2026 |
| JHVIT Total Stock Market Index I | 3.25K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding GUTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 22.6M | 14.18% | +68.94% | Jun 2026 |
| Catalio Capital Management, LP | 6.17M | 3.88% | +12.33% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.10M | 3.83% | +10.19% | Jun 2026 |
| Bank of America Corp | 6.03M | 3.79% | +4,727.74% | Jun 2026 |
| Pale Fire Capital SE | 5.00M | 3.14% | -15.50% | Jun 2026 |
| General Catalyst Group Management, LLC | 4.88M | 3.07% | 0.00% | Jun 2026 |
| Deer Management Co. LLC | 4.77M | 3.00% | 0.00% | Jun 2026 |
| Maverick Capital Ltd | 3.97M | 2.50% | 0.00% | Jun 2026 |
| M28 Capital Management LP | 1.86M | 1.17% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.80M | 1.13% | -15.83% | Jun 2026 |
| Woodline Partners LP | 1.78M | 1.12% | -20.44% | Jun 2026 |
| Jane Street Group LLC | 1.73M | 1.09% | +4,260.78% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.64M | 1.03% | -3.74% | Jun 2026 |
| UBS Group AG | 1.58M | 0.99% | -2.61% | Jun 2026 |
| Geode Capital Management, LLC | 1.32M | 0.83% | -8.29% | Jun 2026 |
| Ikarian Capital, LLC | 1.10M | 0.69% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.08M | 0.68% | +33.78% | Jun 2026 |
| Logos Global Management LP | 1.00M | 0.63% | 0.00% | Jun 2026 |
| Brevan Howard Capital Management LP | 916K | 0.58% | +294.34% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 722K | 0.45% | +19.13% | Jun 2026 |
Fractyl Health, Inc. Common Stock company profile
- Company name
- Fractyl Health, Inc. Common Stock
- Ticker
- GUTS.US
- Exchange
- USA Stocks
- Listed since
- Feb 2, 2024
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 100
- Fiscal year end
- September
- Address
- 3 Van de Graaff Drive, Burlington, MA, United States, 01803
- Phone
- 781 902 8800
- Website
- fractyl.com
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Fractyl Health, Inc. Common Stock management
6- Dr. Harith Rajagopalan M.D., Ph.D.Co-Founder, President, CEO, Director & Principal Executive Officer · born 1976
- Ms. Sarah S. Toomey Esq.General Counsel & Corporate Secretary · born 1975
- Ms. Lara Smith WeberCFO & Treasurer · born 1975
- Mr. Brian LuqueHead of Investor Relations & Corporate Development
- Mr. Jon FitzgeraldSenior Vice President of Regulatory, Quality & Clinical
- Mr. Mike ZumdahlSenior Vice President of Market Access & Commercial Strategy